JP2024510757A5 - - Google Patents

Info

Publication number
JP2024510757A5
JP2024510757A5 JP2023557027A JP2023557027A JP2024510757A5 JP 2024510757 A5 JP2024510757 A5 JP 2024510757A5 JP 2023557027 A JP2023557027 A JP 2023557027A JP 2023557027 A JP2023557027 A JP 2023557027A JP 2024510757 A5 JP2024510757 A5 JP 2024510757A5
Authority
JP
Japan
Prior art keywords
amino acid
necessary
virus
acid sequence
aibp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023557027A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024510757A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/020991 external-priority patent/WO2022198073A1/en
Publication of JP2024510757A publication Critical patent/JP2024510757A/ja
Publication of JP2024510757A5 publication Critical patent/JP2024510757A5/ja
Pending legal-status Critical Current

Links

JP2023557027A 2021-03-18 2022-03-18 炎症細胞または活性化細胞を標的とし、炎症性の状態および疼痛を処置するかまたは改善するための組成物および方法 Pending JP2024510757A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163162714P 2021-03-18 2021-03-18
US63/162,714 2021-03-18
PCT/US2022/020991 WO2022198073A1 (en) 2021-03-18 2022-03-18 Compositions and methods for targeting inflammatory or arctivated cells and treating or ameliorating inflammatory conditions and pain

Publications (2)

Publication Number Publication Date
JP2024510757A JP2024510757A (ja) 2024-03-11
JP2024510757A5 true JP2024510757A5 (enExample) 2025-04-04

Family

ID=83321214

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023557027A Pending JP2024510757A (ja) 2021-03-18 2022-03-18 炎症細胞または活性化細胞を標的とし、炎症性の状態および疼痛を処置するかまたは改善するための組成物および方法

Country Status (10)

Country Link
US (1) US20240209341A1 (enExample)
EP (1) EP4308233A4 (enExample)
JP (1) JP2024510757A (enExample)
KR (1) KR20230159847A (enExample)
CN (1) CN117083381A (enExample)
AU (1) AU2022238450A1 (enExample)
CA (1) CA3212101A1 (enExample)
IL (1) IL305955A (enExample)
MX (1) MX2023010412A (enExample)
WO (1) WO2022198073A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022046919A2 (en) * 2020-08-25 2022-03-03 The Regents Of The University Of California Compositions and methods for the treatment of ocular neuroinflammation
EP4788360A1 (en) * 2023-10-03 2026-08-12 Raft Pharmaceuticals, Inc. Compositions and methods for treating pain disorders
WO2026006723A1 (en) * 2024-06-27 2026-01-02 Anand Rene Reagents and methods for treating headache and migraine pain and co-morbidities thereof
CN121490288A (zh) * 2025-11-21 2026-02-10 中山大学附属第三医院 一种用于急性呼吸窘迫综合征的肺部交感神经局部光遗传激活系统及方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8513702D0 (en) 1985-05-30 1985-07-03 Gill S S Expansible trocar
US5217879A (en) 1989-01-12 1993-06-08 Washington University Infectious Sindbis virus vectors
US5846743A (en) 1995-02-22 1998-12-08 Brigham And Women's Hospital, Inc. Polyphoshoinositide binding peptides for intracellular drug delivery
US5874268A (en) 1996-09-23 1999-02-23 Duke University Method of introducing exogenous compounds into cells by electroporation and apparatus for same
SE9704076D0 (sv) 1997-11-06 1997-11-06 Holdingbolaget Vid Goeteborgs Method for permeabilisation of cell structures and use thereof
US6589503B1 (en) 1998-06-20 2003-07-08 Washington University Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
US20030181366A1 (en) * 2002-03-21 2003-09-25 Yan Luo Peptide inhibitors of Akt and uses thereof
US7343205B1 (en) 2002-08-20 2008-03-11 Boston Scientific Neuromodulation Corp. System and method for insertion of a device into the brain
EP1551292B1 (en) 2002-09-24 2016-04-27 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Imaging method for convection enhanced delivery of therapeutic agents
US20050142141A1 (en) 2002-11-27 2005-06-30 Pardridge William M. Delivery of enzymes to the brain
US20040151766A1 (en) 2003-01-30 2004-08-05 Monahan Sean D. Protein and peptide delivery to mammalian cells in vitro
US20050026823A1 (en) 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
WO2005063156A1 (en) 2003-12-22 2005-07-14 Shear/Kershman Laboratories, Inc. Oral peptide delivery system with improved bioavailability
KR20060123384A (ko) 2003-12-24 2006-12-01 가부시키가이샤 엘티티 바이오파마 약물을 함유하는 나노 입자 및 그 제조 방법, 그리고 당해나노 입자로 이루어지는 비경구 투여용 제제
US8658203B2 (en) 2004-05-03 2014-02-25 Merrimack Pharmaceuticals, Inc. Liposomes useful for drug delivery to the brain
US20070082042A1 (en) 2004-08-06 2007-04-12 Deok-Hoon Park Multiple-layered liposome and preparation method thereof
EP1812074B1 (en) 2004-10-18 2010-12-29 Nitto Denko Corporation Intracellular peptide delivery
US20060129126A1 (en) 2004-11-19 2006-06-15 Kaplitt Michael G Infusion device and method for infusing material into the brain of a patient
JP5639338B2 (ja) 2005-07-27 2014-12-10 プロチバ バイオセラピューティクス インコーポレイティッド リポソームの製造システムおよび製造方法
US20080132878A1 (en) 2006-11-30 2008-06-05 Douglas Kondziolka Device for cell delivery into the brain or body
US8419710B2 (en) 2006-12-06 2013-04-16 Medtronic, Inc. Methods for infusing fluids via an implantable infusion system
US10364275B2 (en) * 2013-05-27 2019-07-30 The Regents Of The University Of California Methods for treating inflammatory responses or diseases caused by inflammation using ApoA-I binding protein (APOA1BP)
HUE055326T2 (hu) * 2015-12-10 2021-11-29 Univ California Készítmények ideggyulladás, neurodegeneráció, neuropátiás fájdalom és migrén kezelésében vagy enyhítésében történõ alkalmazásra

Similar Documents

Publication Publication Date Title
Watson et al. Surfactant proteins A and D: trimerized innate immunity proteins with an affinity for viral fusion proteins
US20200390888A1 (en) Novel aav mediated influenza vaccines
ES2685611T3 (es) Vector VAA8 mejorado con una actividad funcional aumentada y métodos de utilización del mismo
Griffiths et al. The regulation of the CNS innate immune response is vital for the restoration of tissue homeostasis (repair) after acute brain injury: a brief review
JP2021516044A (ja) 抗体回避ウイルスベクターのための方法および組成物
RU2018143411A (ru) Лечение комплемент-опосредуемых расстройств
US12428445B2 (en) Mini-nucleosome core proteins and use in nucleic acid delivery
JP2023551903A5 (enExample)
WO2018057916A1 (en) Novel humanized anti-ebola antibodies useful in preventing ebola infections
TW202214849A (zh) 可溶性enpp1蛋白質及其用途
US20230062096A1 (en) Compositions and methods for treating, ameliorating, and/or preventing diseases or disorders caused by or associated with dnase1 and/or dnase1l3 deficiency
JP2020533968A (ja) 組換えアデノ随伴ベクター
JP2024532426A (ja) エイズウイルス感染の遺伝子治療用の遺伝子配列構築体
JP2024532453A (ja) エイズウイルス感染の遺伝子治療用の遺伝子配列構築体
WO2024229151A2 (en) Multimeric coronavirus binding molecules and uses thereof
TW202532642A (zh) 使用由人類神經或膠細胞產生的重組人類艾杜糖醛酸鹽 (iduronate)-2-硫酸酯酶 (ids) 之黏多醣病ii之治療
US20230372434A1 (en) Method of treating fibrosis with a combination therapy
JP2023521999A (ja) 修飾ミニヌクレオソームコアタンパク質及び核酸送達における使用
White et al. Genetic modification of adeno-associated viral vector type 2 capsid enhances gene transfer efficiency in polarized human airway epithelial cells
US20230026352A1 (en) Suppression of interleukin-17 production and inhibition of th17 cell generation by fibroblasts and products thereof
EP4680734A2 (en) Compositions and methods for treating, ameliorating, and/or preventing diseases and/or disorders
WO2019173707A1 (en) Recombinant adeno-associated viruses encoding serpin peptides and uses thereof
US12617826B2 (en) CLEC2 fusion protein and uses thereof
US20230226158A1 (en) Compositions and methods for treating and/or preventing coagulopathy and/or sepsis in patients suffering from bacterial and/or viral infections
HK40091668A (en) Compositions and methods for treating and/or preventing coagulopathy and/or sepsis in patients suffering from bacterial and/or viral infections